| abstract |
The present application relates to the manufacture of solid dosage forms. The present invention utilizes 3D printing technology, particularly fused filament fabrication (FFF) 3D printing, to produce solid dosage forms, such as pharmaceutical tablets. The production process utilizes novel active ingredient-containing printing filaments, usually on a reel. Such active-containing filaments have been shown to be very robust, and the principles outlined in this disclosure provide a variety of viable formulations directly from 3D printers. This provides, for the first time, a viable means for 3D printing personalized medicines tailored to a patient's needs on-site (eg, in a pharmacy). The present invention also relates to dedicated software for operating printing devices and local, national and global systems for monitoring real-time operation of multiple printing devices so that failures can be easily detected, enabling regulatory approvals and facilitating regulatory compliance. |